These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 18047682)

  • 1. Double knockdown of alpha1,6-fucosyltransferase (FUT8) and GDP-mannose 4,6-dehydratase (GMD) in antibody-producing cells: a new strategy for generating fully non-fucosylated therapeutic antibodies with enhanced ADCC.
    Imai-Nishiya H; Mori K; Inoue M; Wakitani M; Iida S; Shitara K; Satoh M
    BMC Biotechnol; 2007 Nov; 7():84. PubMed ID: 18047682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishment of a GDP-mannose 4,6-dehydratase (GMD) knockout host cell line: a new strategy for generating completely non-fucosylated recombinant therapeutics.
    Kanda Y; Imai-Nishiya H; Kuni-Kamochi R; Mori K; Inoue M; Kitajima-Miyama K; Okazaki A; Iida S; Shitara K; Satoh M
    J Biotechnol; 2007 Jun; 130(3):300-10. PubMed ID: 17559959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineering Chinese hamster ovary cells to maximize effector function of produced antibodies using FUT8 siRNA.
    Mori K; Kuni-Kamochi R; Yamane-Ohnuki N; Wakitani M; Yamano K; Imai H; Kanda Y; Niwa R; Iida S; Uchida K; Shitara K; Satoh M
    Biotechnol Bioeng; 2004 Dec; 88(7):901-8. PubMed ID: 15515168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Highly efficient deletion of FUT8 in CHO cell lines using zinc-finger nucleases yields cells that produce completely nonfucosylated antibodies.
    Malphettes L; Freyvert Y; Chang J; Liu PQ; Chan E; Miller JC; Zhou Z; Nguyen T; Tsai C; Snowden AW; Collingwood TN; Gregory PD; Cost GJ
    Biotechnol Bioeng; 2010 Aug; 106(5):774-83. PubMed ID: 20564614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity.
    Yamane-Ohnuki N; Kinoshita S; Inoue-Urakubo M; Kusunoki M; Iida S; Nakano R; Wakitani M; Niwa R; Sakurada M; Uchida K; Shitara K; Satoh M
    Biotechnol Bioeng; 2004 Sep; 87(5):614-22. PubMed ID: 15352059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.
    Kanda Y; Yamada T; Mori K; Okazaki A; Inoue M; Kitajima-Miyama K; Kuni-Kamochi R; Nakano R; Yano K; Kakita S; Shitara K; Satoh M
    Glycobiology; 2007 Jan; 17(1):104-18. PubMed ID: 17012310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation of FX
    Liu W; Padmashali R; Monzon OQ; Lundberg D; Jin S; Dwyer B; Lee YJ; Korde A; Park S; Pan C; Zhang B
    Biotechnol Prog; 2021 Jan; 37(1):e3061. PubMed ID: 32748555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FX knockout CHO hosts can express desired ratios of fucosylated or afucosylated antibodies with high titers and comparable product quality.
    Louie S; Haley B; Marshall B; Heidersbach A; Yim M; Brozynski M; Tang D; Lam C; Petryniak B; Shaw D; Shim J; Miller A; Lowe JB; Snedecor B; Misaghi S
    Biotechnol Bioeng; 2017 Mar; 114(3):632-644. PubMed ID: 27666939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of cell lines for stable production of fucose-negative antibodies with enhanced ADCC.
    Kanda Y; Yamane-Ohnuki N; Sakai N; Yamano K; Nakano R; Inoue M; Misaka H; Iida S; Wakitani M; Konno Y; Yano K; Shitara K; Hosoi S; Satoh M
    Biotechnol Bioeng; 2006 Jul; 94(4):680-8. PubMed ID: 16609957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular cloning and expression of GDP-D-mannose-4,6-dehydratase, a key enzyme for fucose metabolism defective in Lec13 cells.
    Ohyama C; Smith PL; Angata K; Fukuda MN; Lowe JB; Fukuda M
    J Biol Chem; 1998 Jun; 273(23):14582-7. PubMed ID: 9603974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Production of afucosylated antibodies in CHO cells by coexpression of an anti-FUT8 intrabody.
    Joubert S; Guimond J; Perret S; Malenfant F; Elahi SM; Marcil A; Parat M; Gilbert M; Lenferink AEG; Baardsnes J; Durocher Y
    Biotechnol Bioeng; 2022 Aug; 119(8):2206-2220. PubMed ID: 35509261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-hairpin-RNA-mediated silencing of fucosyltransferase 8 in Chinese-hamster ovary cells for the production of antibodies with enhanced antibody immune effector function.
    Beuger V; Künkele KP; Koll H; Gärtner A; Bähner M; Burtscher H; Klein C
    Biotechnol Appl Biochem; 2009 May; 53(Pt 1):31-7. PubMed ID: 19032154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Potelligent antibodies as next generation therapeutic antibodies].
    Shitara K
    Yakugaku Zasshi; 2009 Jan; 129(1):3-9. PubMed ID: 19122430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies.
    Satoh M; Iida S; Shitara K
    Expert Opin Biol Ther; 2006 Nov; 6(11):1161-73. PubMed ID: 17049014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of the CRISPR/Cas9 Gene Editing Method for Modulating Antibody Fucosylation in CHO Cells.
    Wang Q; Aliyu L; Chung CY; Rosenberg JN; Yu G; Betenbaugh MJ
    Methods Mol Biol; 2024; 2810():249-271. PubMed ID: 38926284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity.
    Shinkawa T; Nakamura K; Yamane N; Shoji-Hosaka E; Kanda Y; Sakurada M; Uchida K; Anazawa H; Satoh M; Yamasaki M; Hanai N; Shitara K
    J Biol Chem; 2003 Jan; 278(5):3466-73. PubMed ID: 12427744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of fucosyltransferase 8 is associated with an unfavorable clinical outcome in non-small cell lung cancers.
    Honma R; Kinoshita I; Miyoshi E; Tomaru U; Matsuno Y; Shimizu Y; Takeuchi S; Kobayashi Y; Kaga K; Taniguchi N; Dosaka-Akita H
    Oncology; 2015; 88(5):298-308. PubMed ID: 25572677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mammalian α-1,6-Fucosyltransferase (FUT8) Is the Sole Enzyme Responsible for the N-Acetylglucosaminyltransferase I-independent Core Fucosylation of High-mannose N-Glycans.
    Yang Q; Wang LX
    J Biol Chem; 2016 May; 291(21):11064-71. PubMed ID: 27008861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Production of non-fucosylated antibodies by co-expression of heterologous GDP-6-deoxy-D-lyxo-4-hexulose reductase.
    von Horsten HH; Ogorek C; Blanchard V; Demmler C; Giese C; Winkler K; Kaup M; Berger M; Jordan I; Sandig V
    Glycobiology; 2010 Dec; 20(12):1607-18. PubMed ID: 20639190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Facile Modulation of Antibody Fucosylation with Small Molecule Fucostatin Inhibitors and Cocrystal Structure with GDP-Mannose 4,6-Dehydratase.
    Allen JG; Mujacic M; Frohn MJ; Pickrell AJ; Kodama P; Bagal D; San Miguel T; Sickmier EA; Osgood S; Swietlow A; Li V; Jordan JB; Kim KW; Rousseau AC; Kim YJ; Caille S; Achmatowicz M; Thiel O; Fotsch CH; Reddy P; McCarter JD
    ACS Chem Biol; 2016 Oct; 11(10):2734-2743. PubMed ID: 27434622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.